Clinical Trial Update: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study of PRT12396 in select myeloproliferative neoplasms is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms
• Polycythemia Vera

Drugs mentioned

• PRT12396

Snippet

Sponsor: Prelude Therapeutics | Conditions: Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Status: RECRUITING